LEO Pharma: LEO Pharma A/S: LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in medic...